Veracyte Gestione
Criteri Gestione verificati 4/4
Veracyte Il CEO è Marc Stapley, nominato in Jun2021, e ha un mandato di 4.92 anni. la retribuzione annua totale è $ 7.42M, composta da 9.4% di stipendio e 90.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.18% delle azioni della società, per un valore di $ 6.50M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.7 anni e 5.2 anni.
Informazioni chiave
Marc Stapley
Amministratore delegato
US$7.4m
Compenso totale
| Percentuale dello stipendio del CEO | 9.43% |
| Mandato del CEO | 4.9yrs |
| Proprietà del CEO | 0.2% |
| Durata media del management | 3.7yrs |
| Durata media del Consiglio di amministrazione | 5.2yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento della narrazione • May 20
VCYT: Mixed Price Revisions Will Pressure Expectations For Future Cash Flow Repricing
Narrative Update Veracyte's updated analyst price target shifts to $37.23 from $38.59, as analysts factor in a slightly higher discount rate, more moderate revenue growth expectations, a higher projected profit margin, and a lower assumed future P/E multiple, informed by recent mixed target revisions and a new bullish initiation. Analyst Commentary Recent research on Veracyte reflects a split view, with some firms turning more constructive while several bearish analysts have trimmed price targets and highlighted execution and valuation risks.Articolo di analisi • May 14
Shareholders Will Be Pleased With The Quality of Veracyte's (NASDAQ:VCYT) Earnings
When companies post strong earnings, the stock generally performs well, just like Veracyte, Inc.'s ( NASDAQ:VCYT...
Aggiornamento della narrazione • Apr 28
VCYT: Revised Street Views Will Highlight Medium Term Revenue Guidance Story
Analysts now see a modestly lower upside for Veracyte, trimming the consensus price target by a few dollars to around the mid $30s. Recent research reflects a balance between reduced targets from several firms and a newer bullish initiation that emphasizes the company's longer term growth potential.Aggiornamento della narrazione • Apr 14
VCYT: Bullish Coverage And Margin Reset Will Strengthen Prostate Cancer Risk Position
Analysts now see Veracyte's fair value at $53, up from $51. This revision reflects updated assumptions around growth, profitability and valuation multiples informed by recent Street research, including both fresh coverage and revised price targets.
Aggiornamento della narrazione • Mar 31
VCYT: Refreshed Models And 2026 Earnings Focus Will Support Long-Term Upside
Analysts have trimmed their average price target on Veracyte by about $1.60 to $47.00, reflecting refreshed models after recent results and updated views on revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent research updates have focused on resetting expectations for Veracyte, with price targets adjusted downward and models refreshed after Q4 results.Aggiornamento della narrazione • Mar 17
VCYT: NCCN Risk Stratification Focus Will Support Future Cash Flow Repricing
Analysts have lowered their price target on Veracyte from $43.00 to about $38.59, citing updated assumptions for revenue growth, profit margins and future P/E following recent model revisions. This includes a reduced $37 target from one large Wall Street firm after Q4 results.Aggiornamento della narrazione • Mar 02
VCYT: 2026 Revenue Outlook And Higher Future P/E Will Lift Long-Term Upside
Analysts now set their Veracyte price target at $48.60, compared with $47.50 previously. This reflects updated views on revenue growth, profit margin assumptions and a higher future P/E multiple.Aggiornamento della narrazione • Feb 16
VCYT: Guideline Support And Margin Reset Will Strengthen Prostate Cancer Risk Role
Analysts have kept their $51.00 price target for Veracyte unchanged, citing updated assumptions that reflect slightly lower discount rates, modestly higher revenue growth expectations, a reduced profit margin outlook, and a higher future P/E multiple. What's in the News Veracyte issued earnings guidance for the fourth quarter of 2025, with expected total revenue between US$138 million and US$140 million, described as 16% to 18% growth for the period.Aggiornamento della narrazione • Feb 02
VCYT: NCCN Risk Stratification Focus Will Support Future Genomic Test Adoption
Narrative Update on Veracyte Analysts have kept their Veracyte fair value target steady at $43.00, citing updated NCCN prostate cancer guidelines that highlight Decipher’s role in risk stratification and support slightly adjusted assumptions for revenue growth, profit margins, and future P/E. Analyst Commentary Recent commentary points to the updated NCCN prostate cancer guidelines as a supportive data point for Veracyte’s Decipher test.Aggiornamento della narrazione • Jan 19
VCYT: NCCN Guideline Support Will Strengthen Prostate Cancer Risk Stratification Role
Analysts have lifted their price target on Veracyte from US$45.00 to US$51.00, citing updated NCCN guidelines that they view as incrementally favorable for the company’s Decipher prostate cancer test and its differentiation based on clinical evidence. Analyst Commentary Bullish analysts are framing the latest NCCN prostate cancer guideline update as a meaningful support for Veracyte’s Decipher test, especially around how it is positioned within risk stratification.Seeking Alpha • Jan 16
Veracyte: Profitable, De-Risked, And Ready To Run
Summary Veracyte (VCYT) has transitioned to a profitable, diversified model with strong operating leverage and self-fortifying balance sheet. Key 2025-2026 catalysts include deeper prostate cancer penetration, entry into minimal residual disease, and U.S. re-launch of the Prosigna breast cancer test. VCYT projects 16% revenue growth to $515–$517M in FY25 and >25% adjusted EBITDA margin, signaling sustained profitable execution. A robust digital pathology database and AI-driven bioinformatics platform create significant competitive moats and future product opportunities. Read the full article on Seeking AlphaAggiornamento della narrazione • Jan 05
VCYT: NCCN Guideline Support Will Shape Future Decipher Adoption And Competitive Risks
Analysts have lifted their price target on Veracyte from $28.40 to $43.00, citing updated NCCN prostate cancer guidelines that highlight the Decipher test in key risk stratification tables as support for a higher fair value assumption. Analyst Commentary Analysts point to the updated NCCN V3.2026 prostate cancer guidelines as a supportive data point for Veracyte, highlighting that Decipher is explicitly listed in the principles of risk stratification tables across several key prostate cancer settings.Aggiornamento della narrazione • Dec 15
VCYT: Updated NCCN Guidelines Will Support Gradual Risk Stratification Adoption
Analysts have modestly raised their price target on Veracyte to approximately $47.50 from about $46.30, citing slightly stronger long term growth and profitability expectations, as well as the incremental boost from updated NCCN guidelines that further differentiate the company’s Decipher prostate cancer test. Analyst Commentary Street research characterizes the NCCN guideline update as a net positive for Veracyte, with the Decipher prostate cancer test receiving prominent placement in risk stratification tables across multiple disease stages.Aggiornamento della narrazione • Nov 29
VCYT: New NCCN Guidelines Will Support Continued Market Differentiation
Analysts have raised their price target for Veracyte from $45.30 to $46.30, citing ongoing positive inclusion of the company’s Decipher test in updated clinical guidelines as a contributing factor. Analyst Commentary Analysts have examined the recent updates to the clinical guidelines and their implications for Veracyte’s Decipher test, highlighting both opportunities and potential challenges facing the company.Articolo di analisi • Nov 22
Veracyte, Inc. (NASDAQ:VCYT) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Despite an already strong run, Veracyte, Inc. ( NASDAQ:VCYT ) shares have been powering on, with a gain of 27% in the...Aggiornamento della narrazione • Nov 15
VCYT: Expanded Prostate Cancer Guidelines Will Drive Demand Ahead
Veracyte's analyst price target has been raised from $41.10 to $45.30. Analysts cite stronger guidelines support, as well as improved revenue and profit growth expectations, as key drivers.Aggiornamento della narrazione • Nov 01
VCYT: Continued Pipeline Success Will Drive Broader Health Market Expansion
Narrative Update: Veracyte Analyst Price Target Revision Analysts have slightly reduced their price target for Veracyte, lowering it by $1 to $28. They cite solid recent performance but note that larger upside may be realized further into the future.Aggiornamento della narrazione • Oct 18
Advanced Genomic And Cancer Diagnostics Will Expand Global Health Markets
Analysts have modestly raised Veracyte’s fair value estimate to $41.22 from $39.75. They cite continued product momentum and optimistic guidance, despite lingering longer-term uncertainties.Articolo di analisi • Aug 30
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Veracyte, Inc. ( NASDAQ:VCYT ) shareholders would be excited to see that the share price has had a great month, posting...Articolo di analisi • Jun 15
Veracyte, Inc.'s (NASDAQ:VCYT) Shares Lagging The Industry But So Is The Business
You may think that with a price-to-sales (or "P/S") ratio of 4.5x Veracyte, Inc. ( NASDAQ:VCYT ) is a stock worth...Articolo di analisi • May 10
Veracyte, Inc. Just Beat EPS By 260%: Here's What Analysts Think Will Happen Next
As you might know, Veracyte, Inc. ( NASDAQ:VCYT ) just kicked off its latest quarterly results with some very strong...Nuova narrazione • May 07
Decipher, Afirma And MRD Tests Will Broaden Future Markets
Veracyte’s Decipher test expansion and updated NCCN guidelines could drive significant revenue growth and market share in the prostate cancer segment.Articolo di analisi • Mar 08
Shareholders Can Be Confident That Veracyte's (NASDAQ:VCYT) Earnings Are High Quality
Even though Veracyte, Inc. ( NASDAQ:VCYT ) posted strong earnings, investors appeared to be underwhelmed. We have done...Articolo di analisi • Mar 04
Veracyte, Inc. (NASDAQ:VCYT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Veracyte, Inc. ( NASDAQ:VCYT ) shareholders that were waiting for something to happen have been dealt a blow with a 26...Articolo di analisi • Jan 09
Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 50% Above Its Share Price
Key Insights Veracyte's estimated fair value is US$65.48 based on 2 Stage Free Cash Flow to Equity Veracyte is...Seeking Alpha • Dec 11
Veracyte: Getting Frothy
Summary Veracyte has seen its stock more than double since early August, driven by strong Q3 results and increased revenue guidance for FY2024. This medical diagnostic firm focused on oncology is executing well, but the stock looks a bit 'frothy' based on some valuation metrics. The analyst community is also somewhat mixed based on the stock's valuation, and there was some notable insider selling following Q3 results. Can the rally continue in Veracyte? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaArticolo di analisi • Dec 01
Veracyte, Inc. (NASDAQ:VCYT) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Veracyte, Inc. ( NASDAQ:VCYT ) shares have continued their recent momentum with a 25% gain in the last month alone. The...Articolo di analisi • Aug 18
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 42%
Veracyte, Inc. ( NASDAQ:VCYT ) shareholders have had their patience rewarded with a 42% share price jump in the last...Articolo di analisi • Aug 09
Veracyte, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Shareholders will be ecstatic, with their stake up 39% over the past week following Veracyte, Inc. 's ( NASDAQ:VCYT...Articolo di analisi • Jul 02
Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 76% Above Its Share Price
Key Insights The projected fair value for Veracyte is US$37.52 based on 2 Stage Free Cash Flow to Equity Veracyte's...Articolo di analisi • Jun 06
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking
Veracyte, Inc.'s ( NASDAQ:VCYT ) price-to-sales (or "P/S") ratio of 4.4x might make it look like a strong buy right now...Articolo di analisi • May 09
Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Veracyte, Inc. ( NASDAQ:VCYT ) investors will be delighted, with the company turning in some strong numbers with its...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$88m |
| Dec 31 2025 | US$7m | US$700k | US$66m |
| Sep 30 2025 | n/a | n/a | US$30m |
| Jun 30 2025 | n/a | n/a | US$26m |
| Mar 31 2025 | n/a | n/a | US$33m |
| Dec 31 2024 | US$7m | US$675k | US$24m |
| Sep 30 2024 | n/a | n/a | -US$9m |
| Jun 30 2024 | n/a | n/a | -US$54m |
| Mar 31 2024 | n/a | n/a | -US$68m |
| Dec 31 2023 | US$7m | US$650k | -US$74m |
| Sep 30 2023 | n/a | n/a | -US$50m |
| Jun 30 2023 | n/a | n/a | -US$29m |
| Mar 31 2023 | n/a | n/a | -US$30m |
| Dec 31 2022 | US$5m | US$625k | -US$37m |
| Sep 30 2022 | n/a | n/a | -US$43m |
| Jun 30 2022 | n/a | n/a | -US$49m |
| Mar 31 2022 | n/a | n/a | -US$48m |
| Dec 31 2021 | US$6m | US$350k | -US$76m |
Compensazione vs Mercato: La retribuzione totale di Marc ($USD 7.42M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 7.11M ).
Compensazione vs guadagni: La retribuzione di Marc è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Marc Stapley (55 yo)
4.9yrs
Mandato
US$7,421,877
Compensazione
Mr. Marc A. Stapley serves as Chief Executive Officer at Veracyte, Inc. since June 1, 2021 and serves as its Director since June 08, 2021. He served as the Chief Executive Officer of Helix OpCo, LLC from A...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 4.9yrs | US$7.42m | 0.18% $ 6.5m | |
| Executive VP & CFO | 4.8yrs | US$2.88m | 0.045% $ 1.6m | |
| Chief Scientific & Medical Officer | 2.6yrs | US$2.50m | 0.040% $ 1.4m | |
| Executive VP | 4.3yrs | US$2.79m | 0.0014% $ 51.2k | |
| Global Chief Commercial Officer | 3.7yrs | US$3.20m | 0.023% $ 830.4k | |
| Senior Vice President of Global Operations | 1.5yrs | Nessun dato | Nessun dato | |
| VP & Chief Accounting Officer | 4.3yrs | Nessun dato | 0.0099% $ 355.5k | |
| Chief Development and Technology Officer | less than a year | Nessun dato | Nessun dato | |
| Senior VP & Chief Information Officer | 4.3yrs | Nessun dato | Nessun dato | |
| Director of Investor Relations | no data | Nessun dato | Nessun dato | |
| Senior Vice President of Corporate Marketing | 2.3yrs | Nessun dato | Nessun dato | |
| Chief Human Resources Officer | less than a year | Nessun dato | Nessun dato |
3.7yrs
Durata media
53yo
Età media
Gestione esperta: Il team dirigenziale di VCYT è considerato esperto (durata media dell'incarico 3.7 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 4.9yrs | US$7.42m | 0.18% $ 6.5m | |
| Independent Director | 13.4yrs | US$324.99k | 0.0053% $ 191.5k | |
| Independent Director | 18.3yrs | US$324.99k | 0.025% $ 905.8k | |
| Independent Chair | 11.3yrs | US$359.99k | 0.067% $ 2.4m | |
| Independent Director | 5.8yrs | US$327.49k | 0.022% $ 808.1k | |
| Independent Director | 1.7yrs | US$307.49k | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 5.2yrs | US$309.99k | 0.038% $ 1.4m | |
| Independent Director | 1.7yrs | US$304.99k | Nessun dato | |
| Independent Director | 3.8yrs | US$304.99k | 0.044% $ 1.6m |
5.2yrs
Durata media
62yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di VCYT sono considerati esperti (durata media dell'incarico 5.2 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/21 23:10 |
| Prezzo dell'azione a fine giornata | 2026/05/21 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Veracyte, Inc. è coperta da 24 analisti. 11 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Sung Ji Nam | BTIG |
| Kyle Mikson | Canaccord Genuity |